A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy

Summary

This is a randomized, double-blind, placebo-controlled, sequential, 5-day treatment, ascending dose study in subjects with obstructive HCM aged 18-70 years. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CT-G20.

Timeline

Start

2020-10-23

Primary completion

2022-11-22

Completion

2022-11-22

Outcome

Outcome not reported

Stopped: “The termination criteria of the protocol was met during dose escalation”

Drugs

Indications